Venezuela’s current growth is generally described as unsustainable, with various negative scenarios put forth, including spiraling debt, inflation, and balance of payments crises. However, these pessimistic forecasts have been far off the mark for most of the past decade. This paper looks at...

This report uses data from the Bureau of Labor Statistics Consumer Expenditure Survey from 2004 to 2006 as well as data from the Congressional Budget Office to analyze the savings in prescription drug spending for seniors as a result of the Medicare Prescription Drug, Improvement, and...

Economists are increasingly coming to the recognition that the current downturn is likely to be longer and more severe than they had expected at the time the last stimulus package was approved in February. As a result, there is likely to be interest in additional stimulus in order to boost the...

This report shows that the $787 billion included in the 2009 ARRA will not have as much of an immediate effect on the economy as initially anticipated. After subtracting the annual AMT patch and acounting for state level spending and tax cuts, the full effect of federal stimulus will equal a...

This paper continues a debate over the extent of economic and social progress in Venezuela that began with an article in the March/April 2008 issue of Foreign Affairs. This article argued that “a close look at the evidence reveals just how much Chávez's 'revolution' has hurt Venezuela's...

This paper looks at allegations against the government of Venezuela in Foreign Affairs' recently published article, "An Empty Revolution: The Unfulfilled Promises of Hugo Chávez" (March/April 2008), in light of available data. It shows that some of the allegations are altogether wrong, and...

This paper proposes publicly funding prescription drug trials as an alternative to the present system wherein pharmaceutical companies often finance and conduct tests of their drugs themselves. The report posits that in addition to substantial savings for the government, independent companies...

The rate of new drug development has stagnated, in spite of large increases in both private and public sector spending on biomedical research. The flip side of slower progress is higher drug costs. The cost of developing new drugs has been rising at an average real rate of more than 7 percent...

Projected costs for Medicare Part D have been revised downward, causing some analysts to claim that the program has proven itself a success. This report explores the factors behind the lower cost projections and reaches far different conclusions. It finds two main reasons: 1) a slowdown in the...

With the debate over health care dragging on, it is becoming increasingly likely that the Senate will pass a bill through the reconciliation process, requiring just a simple majority rather than the super-majority needed to break a filibuster. This paper shows that if this path is taken,...